GO
Loading...

Enter multiple symbols separated by commas

Stocks Johnson & Johnson

More

  • There's more to Merck's Ebola vaccine than money Friday, 31 Jul 2015 | 2:18 PM ET
    A file photo of an Ebola vaccine trial in Liberia last February.

    A vaccine being developed by Merck and NewLink was shown to be 100 percent effective, but does this mean they'll make big bucks?

  • LONDON, July 31- Scientists and drug companies will continue to research the potential of alternative Ebola vaccines, despite a shot from Merck and NewLink Genetics proving 100 percent effective in a trial in Guinea. In the event, it proved about as safe as a flu vaccine, said University of Reading virologist Ben Neuman, but it was still not given to children or...

  • "It's very significant for us," Chief Executive Andrea Pfeifer told Reuters. It had disappointing results in a mid-stage trial last year but Roche has been encouraged by the promise of drugs from Eli Lilly and Biogen that work in a similar way and believes it can do better by raising the dose. AC Immune, backed by SAP co-founder Dietmar Hopp, received an undisclosed...

  • UPDATE 1-Interpublic reports better-than-expected revenue Wednesday, 22 Jul 2015 | 7:38 AM ET

    July 22- Advertising company Interpublic Group of Cos Inc's revenue trumped expectations for the seventh straight quarter as higher advertising spending by U.S. businesses made up for the strong dollar's impact on international revenue. U.S. revenue increased about 8 percent while international revenue dropped about 7 percent in the second quarter ended...

  • July 21- Novavax Inc said its experimental Ebola vaccine induced a substantial immune response to the deadly infection in an early-stage trial involving 230 healthy adults. Potential partners include the Biomedical Advanced Research and Development Authority, a division of U.S. Department of Health and Human Services, which Novavax is already working...

  • Novavax rises on promising Ebola vaccine trial Tuesday, 21 Jul 2015 | 9:39 AM ET
    In this handout from the Center for Disease Control, a colorized transmission electron micrograph (TEM) of a Ebola virus virion is seen.

    Novavax shares rose at Tuesday's market open after the bio-pharmaceutical firm said its Ebola vaccine showed promising early results.

  • July 21- Novavax Inc said its experimental Ebola vaccine induced a substantial immune response to the deadly infection in an early-stage trial involving 230 healthy adults. Vaccines being developed by Bavarian Nordic, GlaxoSmithKline and Johnson& Johnson have entered mid-stage studies. Gaithersburg, Maryland- based Novavax's shares have risen more than...

  • Cramer: Johnson & Johnson needs to break up—NOW! Monday, 20 Jul 2015 | 6:35 PM ET
    Johnson & Johnson products

    Jim Cramer makes the case as to why Johnson & Johnson cannot wait another day to break itself up.

  • Revenue recession's real, and the trend isn't good Thursday, 16 Jul 2015 | 9:56 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Earnings season is in full swing, and once again there are considerable worries about what some are calling a "revenue recession."

  • Stocks close mildly lower as Greece vote looms Wednesday, 15 Jul 2015 | 4:00 PM ET
    Traders on the floor of the New York Stock Exchange.

    U.S. stocks closed mildly lower on Wednesday as investors remained anxious ahead of an impending Greek parliament vote.

  • Cramer Remix: Wake up or you'll miss these stocks Tuesday, 14 Jul 2015 | 7:21 PM ET
    Jim Cramer on Mad Money.

    Jim Cramer calls out the biotech winners that are trading higher in this market.

  • Cramer: Beware! Expensive earnings season mistakes Tuesday, 14 Jul 2015 | 6:11 PM ET
    A gas flare is seen at an oil well near Williston, North Dakota.

    Jim Cramer now calls it mistake season instead of earnings season. Don't let these expensive mistakes ruin your portfolio!

  • Traders on the floor of the New York Stock Exchange.

    U.S. stocks closed higher as second-quarter earnings season began and investors eyed developments in Greece and a slight recovery in oil prices.

  • July 14- Johnson& Johnson on Tuesday reported sharply lower sales in the second quarter, and cited a stronger U.S. dollar, disappointing sales of its medical devices and plunging demand for a hepatitis C drug faced with strong competition. J&J said medical device sales fell 12.2 percent in the quarter to $6.36 billion, following the recent sale of the company's...

  • *JPMorgan profit beats estimates; Wells Fargo revenue misses. Twitter jumped as much as 8.5 percent to $38.82 after a report, purportedly from Bloomberg, that the company was made a $31 billion offer. Micron jumped as much as 12.4 percent and was the biggest gainer on the S&P 500. China's state-backed Tsinghua Unigroup Ltd is preparing a $23 billion bid for the U.S....

  • US STOCKS-Wall St slightly higher as oil prices recover Tuesday, 14 Jul 2015 | 10:20 AM ET

    *JPMorgan profit beats estimates; Wells Fargo revenue misses. U.S. companies are expected to report their worst sales decline in nearly six years when they post second-quarter results, while earnings are expected to have fallen 2.9 percent, according to Thomson Reuters estimates data. "The focus is shifting from macro factors to micro as we head into earnings...

  • Banks, retail, Iran may steal thunder from Greece Tuesday, 14 Jul 2015 | 9:20 AM ET
    Traders on the floor of the New York Stock Exchange.

    The market could shift focus away from Greece on Tuesday and instead focus on earnings.

  • July 14- Johnson& Johnson reported a better-than-expected profit as sales of its older drugs helped to offset the impact of a strong dollar on revenue from outside the United States. The healthcare conglomerate raised its profit forecast to $6.10- $6.20 per share, from $6.04- $6.19. The company's net profit rose to $4.52 billion, or $1.61 per share, in the second...

  • Johnson & Johnson earnings top expectations Tuesday, 14 Jul 2015 | 8:06 AM ET

    Johnson & Johnson delivered quarterly earnings that topped analysts' expectations on Tuesday.

  • J&J profit rises 4 pct on pharma sales Tuesday, 14 Jul 2015 | 7:57 AM ET

    July 14- Johnson& Johnson reported a 4 percent rise in quarterly profit as sales of its mainstay older drugs managed to offset the impact of a strong dollar on overseas revenue. The company's net profit rose to $4.52 billion, or $1.61 per share, in the second quarter, from $4.33 billion, or $1.51 per share, a year earlier. Excluding special items, the company earned...